A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies

av Benepal, T, Jackman, A, Pyle, L, Bate, S, Hardcastle, A, Aherne, W, Mitchell, F, Simmons, L, Ruddle, R, Raynaud, F, Gore, M
Publicerad 2005

A phase I study of the nitroimidazole hypoxia marker SR4554 using (19)F magnetic resonance spectroscopy

av Lee, C P, Payne, G S, Oregioni, A, Ruddle, R, Tan, S, Raynaud, F I, Eaton, D, Campbell, M J, Cross, K, Halbert, G, Tracy, M, McNamara, J, Seddon, B, Leach, M O, Workman, P, Judson, I
Publicerad 2009

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

av Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., de Bono, J.S.
I publikationen Ann Oncol (2020)

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

av Basu, B, Krebs, M G, Sundar, R, Wilson, R H, Spicer, J, Jones, R, Brada, M, Talbot, D C, Steele, N, Ingles Garces, A H, Brugger, W, Harrington, E A, Evans, J, Hall, E, Tovey, H, de Oliveira, F M, Carreira, S, Swales, K, Ruddle, R, Raynaud, F I, Purchase, B, Dawes, J C, Parmar, M, Turner, A J, Tunariu, N, Banerjee, S, de Bono, J S, Banerji, U
I publikationen Ann Oncol (2018)